ES2371479T3 - Uso de aimp2dx2 para el diagnóstico y tratamiento del cáncer. - Google Patents

Uso de aimp2dx2 para el diagnóstico y tratamiento del cáncer. Download PDF

Info

Publication number
ES2371479T3
ES2371479T3 ES05819055T ES05819055T ES2371479T3 ES 2371479 T3 ES2371479 T3 ES 2371479T3 ES 05819055 T ES05819055 T ES 05819055T ES 05819055 T ES05819055 T ES 05819055T ES 2371479 T3 ES2371479 T3 ES 2371479T3
Authority
ES
Spain
Prior art keywords
aimp2
aimp2dx2
protein
cancer
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES05819055T
Other languages
English (en)
Spanish (es)
Inventor
Sunghoon Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neomics Co Ltd
Original Assignee
Neomics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neomics Co Ltd filed Critical Neomics Co Ltd
Application granted granted Critical
Publication of ES2371479T3 publication Critical patent/ES2371479T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES05819055T 2004-11-24 2005-11-18 Uso de aimp2dx2 para el diagnóstico y tratamiento del cáncer. Active ES2371479T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20040097164 2004-11-24
KR20040097164 2004-11-24
KR20050039073 2005-05-10
KR1020050039073A KR20060057992A (ko) 2004-11-24 2005-05-10 ｐ38-ＤＸ2 및 이의 용도

Publications (1)

Publication Number Publication Date
ES2371479T3 true ES2371479T3 (es) 2012-01-03

Family

ID=37153221

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05819055T Active ES2371479T3 (es) 2004-11-24 2005-11-18 Uso de aimp2dx2 para el diagnóstico y tratamiento del cáncer.

Country Status (5)

Country Link
JP (1) JP4718556B2 (ja)
KR (1) KR20060057992A (ja)
CN (1) CN101087804B (ja)
AT (1) ATE521631T1 (ja)
ES (1) ES2371479T3 (ja)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9944713B2 (en) 2004-11-24 2018-04-17 Medicinal Bioconvergence Research Center Antibody specific to the AIMP2-DX2
JP6008844B2 (ja) * 2010-05-04 2016-10-19 エータイアー ファーマ， インコーポレイテッド ｐ３８ＭＵＬＴＩ−ｔＲＮＡ合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2014111553A1 (de) * 2013-01-17 2014-07-24 Sit Soft Intelligent Therapeutics Gmbh & Co Kg Selektives zelltod-induzierendes binäres enzymsystem
KR102297505B1 (ko) * 2016-03-07 2021-09-01 재단법인 의약바이오컨버젼스연구단 Aimp2-dx2와 hsp70의 결합을 저해하는 항암제 스크리닝 방법
KR101831435B1 (ko) * 2016-03-10 2018-02-22 재단법인 의약바이오컨버젼스연구단 Aimp2-dx2 단백질에 특이적으로 결합하는 항체
EP3375871A1 (en) * 2017-03-13 2018-09-19 SIT Biotech GmbH Selective cell death-inducing enzyme system
KR102248420B1 (ko) * 2019-03-15 2021-05-06 주식회사 제너로스 miR-142-3p의 표적 서열을 포함하는 재조합 벡터

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100575251B1 (ko) * 2003-03-03 2006-05-02 재단법인서울대학교산학협력재단 ｐ38／ＪＴＶ－1을 유효성분으로 하는 암 치료용 약학적조성물 및 암 치료용 약학적 조성물의 스크리닝 방법

Also Published As

Publication number Publication date
CN101087804B (zh) 2012-07-04
KR20060057992A (ko) 2006-05-29
JP2008521398A (ja) 2008-06-26
JP4718556B2 (ja) 2011-07-06
ATE521631T1 (de) 2011-09-15
CN101087804A (zh) 2007-12-12

Similar Documents

Publication Publication Date Title
EP1814909B1 (en) Use of aimp2dx2 for the diagnosis and treatment of cancer
US8003780B2 (en) AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2
US6689744B2 (en) Notch receptor agonists and uses
ES2371479T3 (es) Uso de aimp2dx2 para el diagnóstico y tratamiento del cáncer.
US8809291B2 (en) Id-1 gene and gene products as therapeutic targets for treatment of breast cancer and other types of carcinoma
JP2005521418A (ja) ヒト・リボヌクレオチド還元酵素ｍ２サブユニット
JP5836940B2 (ja) ソリシジン由来ペプチドならびにｔｒｐｖ−６がんの検出および薬剤送達のための方法
US5654406A (en) Antibody to ERBB2 promoter binding factor
JP2008513462A (ja) ｐ５３−依存性および非依存性ガン抑制の調節因子としてのＡＲＦ−ＢＰ１、およびその使用
JP4365583B2 (ja) ノッチレセプターアゴニスト及び用途
AU2001292750A1 (en) Notch receptor agonists and uses
KR20070113926A (ko) 암의 진단과 치료를 위한 ａｉｍｐ2ｄｘ2의 용도
TW200831898A (en) Treatment of insulin resistance
US7419792B2 (en) Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody
ES2805206T3 (es) Enfoque dirigido a GDF6 y a señalización de BMP para la terapia contra el melanoma
US10023915B2 (en) Method for screening for a cancer treatment agent using the interaction between PAUF and a binding partner thereof
CN110234773A (zh) 治疗含融合基因的癌症的方法